Zhangzhou Pientzehuang Pharmaceutical., Ltd Website

Zhangzhou Pientzehuang Pharmaceutical., Ltd

SHSE-600436

Basic

  • Market Cap

    CN¥130.79B

  • EV

    CN¥130.26B

  • Shares Out

    603.32M

  • Revenue

    CN¥10.6B

  • Employees

    2,789

Margins

  • Gross

    46.45%

  • EBITDA

    33.38%

  • Operating

    32.69%

  • Pre-Tax

    33.96%

  • Net

    28.32%

  • FCF

    18.56%

Returns (5Yr Avg)

  • ROA

    18.75%

  • ROTA

    23.8%

  • ROE

    23.23%

  • ROCE

    25.68%

  • ROIC

    37.81%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    CN¥281.32

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    CN¥2,374.64M

  • Net Debt

    -CN¥1,102.16M

  • Debt/Equity

    0.09

  • EBIT/Interest

    94.32

Growth (CAGR)

  • Rev 3Yr

    15.96%

  • Rev 5Yr

    16.08%

  • Rev 10Yr

    22.13%

  • Dil EPS 3Yr

    19.34%

  • Dil EPS 5Yr

    19.78%

  • Dil EPS 10Yr

    20.38%

  • Rev Fwd 2Yr

    14.31%

  • EBITDA Fwd 2Yr

    16.17%

  • EPS Fwd 2Yr

    18.57%

  • EPS LT Growth Est

    19.25%

Dividends

  • Yield

  • Payout

    46.59%

  • DPS

    CN¥2.32

  • DPS Growth 3Yr

    37.11%

  • DPS Growth 5Yr

    31.06%

  • DPS Growth 10Yr

    22.98%

  • DPS Growth Fwd 2Yr

    6.6%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Operating Revenues

5,705.9

6,492.5

8,004.3

8,674.5

10,036.2

10,577.4

Other Revenues, Total

16.3

18.3

17.3

19.5

22.3

22.3

Total Revenues

5,722.3

6,510.8

8,021.6

8,694

10,058.5

10,599.7

Total Revenues % Chg.

20.1%

13.8%

23.2%

8.4%

15.7%

18.1%

Cost of Goods Sold, Total

3,198.4

3,584.3

3,968

4,734.9

5,363.2

5,676.1

Gross Profit

2,523.8

2,926.5

4,053.6

3,959.1

4,695.3

4,923.6

Selling General & Admin Expenses, Total

796.2

982.2

1,027.2

814.4

1,149.8

1,147.1

Provision for Bad Debts

2.8

1.9

7.1

-6.8

12.3

19.1

R&D Expenses

119.4

97.6

199.5

230

232.4

228.3

Other Operating Expenses

45.9

53.2

72.1

72

70.8

64.2

Other Operating Expenses, Total

964.3

1,134.9

1,305.9

1,109.6

1,465.2

1,458.7

Operating Income

1,559.5

1,791.6

2,747.7

2,849.5

3,230.1

3,464.9

Interest Expense, Total

-31.1

-27.4

-32.9

-38

-37.3

-36.7

Interest And Investment Income

95.3

149.3

144.5

171.6

170.8

170.8

Net Interest Expenses

64.2

121.9

111.6

133.6

133.5

134

Currency Exchange Gains (Loss)

4.7

-3.3

-3.3

7.2

3.1

3.1

Other Non Operating Income (Expenses)

-2.7

-4.4

-21.6

-36.5

6

9.5

EBT, Excl. Unusual Items

1,625.7

1,905.8

2,834.4

2,953.8

3,372.7

3,611.6

Impairment of Goodwill

-6.1

Gain (Loss) On Sale Of Investments

-0

6.7

4.5

-0

8.3

-4.4

Gain (Loss) On Sale Of Assets

4.6

40.3

27.6

11.1

1.3

1.5

Asset Writedown

-1

-0.3

4.5

Other Unusual Items

20.4

26.1

3.6

13.2

-13.4

-13.8

EBT, Incl. Unusual Items

1,644.6

1,978.9

2,869

2,977.7

3,368.9

3,599.3

Income Tax Expense

257.7

289.5

404.2

454.8

517.8

546.1

Earnings From Continuing Operations

1,386.9

1,689.4

2,464.8

2,523

2,851.1

3,053.3

Minority Interest

-12.6

-17.8

-32.9

-50.6

-53.8

-51.1

Net Income

1,374.4

1,671.5

2,431.9

2,472.3

2,797.4

3,002.2

Net Income to Common Incl Extra Items

1,374.4

1,671.5

2,431.9

2,472.3

2,797.4

3,002.2

Net Income to Common Excl. Extra Items

1,374.4

1,671.5

2,431.9

2,472.3

2,797.4

3,002.2

Total Shares Outstanding

603.3

603.3

603.3

603.3

603.3

603.3

Weighted Avg. Shares Outstanding

602.8

603.4

603.4

603

602.9

602.9

Weighted Avg. Shares Outstanding Dil

602.8

603.4

603.4

603

602.9

602.9

EPS

2.3

2.8

4

4.1

4.6

5

EPS Diluted

2.3

2.8

4

4.1

4.6

5

EBITDA

1,615.4

1,881.8

2,853.9

2,896.8

3,297.9

3,537.8

Effective Tax Rate

15.7%

14.6%

14.1%

15.3%

15.4%

15.2%